INS and type 2 diabetes mellitus: In a clinical trial of patients with T2D using non-insulin therapies and a high 10-year predicted atherosclerotic cardiovascular disease risk (24.0%), CGM use was associated with a significant decrease in atherosclerotic cardiovascular disease risk to 16.3% at 16 weeks, as well as a significant decrease in HbA1c, diabetes distress scale, cholesterol, and triglycerides (65).